BackgroundCheck.run
Search For

Arthur W Lo, 40State College, PA

Related to:
Shirley L Locheng 28 Shirley Locheng 72

Arthur Lo Phones & Addresses

State College, PA   

Walnut Creek, CA   

Darby, PA   

Get Report
Control this profile

Mentions for Arthur W Lo

Arthur Lo resumes & CV records

Resumes

Arthur Lo Photo 32

Arthur Lo

Arthur Lo Photo 33

Arthur Lo

Publications & IP owners

Us Patents

Method And Apparatus For Modeling Atherosclerosis

US Patent:
2008024, Oct 9, 2008
Filed:
Oct 19, 2007
Appl. No.:
11/875809
Inventors:
Kapil GADKAR - Mountain View CA, US
Ananth Kadambi - San Mateo CA, US
Kortney Leabourne - Redwood City CA, US
Arthur Lo - San Francisco CA, US
Thomas S. Paterson - Redondo Beach CA, US
Lynn Powell - San Mateo CA, US
International Classification:
G06F 17/10
G06G 7/60
US Classification:
703 2, 703 11
Abstract:
The invention encompasses novel computer models of atherosclerosis and systems for predicting development and progression of atherosclerosis as well as associated cardiovascular risk. In particular, the computer model of atherosclerosis comprises a) a cholesterol metabolism module; b) an atherogenesis module; and c) a plaque stability module. The computer model optionally further comprises a cardiovascular risk module.

Method Of Treating A Patient Infected With A Coronavirus And Having A Baseline Level Of Crp Below 150 Mg/L

US Patent:
2023002, Jan 26, 2023
Filed:
Jun 20, 2022
Appl. No.:
17/844593
Inventors:
- South San Francisco CA, US
Tuan Stevon Nguyen - Pleasanton CA, US
David A. Lombardi - Natick MA, US
Glenn D. Crater - Raleigh NC, US
Edmund J. Moran - San Francisco CA, US
Nathan David Pfeifer - Montara CA, US
Wayne Arthur Yates - San Mateo CA, US
Kyla Dee-Kinnick Kennedy - Clive IA, US
Joseph Budman - Redwood City CA, US
Arthur Lo - San Francisco CA, US
International Classification:
A61K 31/437
A61K 31/573
A61K 31/675
A61P 31/14
Abstract:
Provided herein are methods of treating a patient infected with a coronavirus and having a baseline level of CRP below 150 mg/L, comprising administering to the patient a compound of formula 1:or a pharmaceutically-acceptable salt thereof.

Administration Of Gut-Selective Jak3 Inhibitor

US Patent:
2021035, Nov 18, 2021
Filed:
May 10, 2021
Appl. No.:
17/315898
Inventors:
- South San Francisco CA, US
David L. BOURDET - South San Francisco CA, US
Ai Ling CHING - South San Francisco CA, US
Arthur LO - South San Francisco CA, US
International Classification:
A61K 31/416
Abstract:
Methods of safely administrating a gut-selective JAK3 inhibitor by oral administration are described. Also described are methods for providing clinically proven safe treatment of gastrointestinal inflammatory diseases, such as celiac disease, by oral administration of a gut-selective JAK3 inhibitor.

Method Of Treating A Patient Infected With A Coronavirus With A Dimethyl Amino Azetidine Amide Compound

US Patent:
2021034, Nov 11, 2021
Filed:
May 7, 2021
Appl. No.:
17/302594
Inventors:
- South San Francisco CA, US
Edmund J. Moran - San Francisco CA, US
Rajeev Saggar - Scottsdale AZ, US
Nathan David Pfeifer - Montara CA, US
Wayne Arthur Yates - San Mateo CA, US
Kyla Dee-Kinnick Kennedy - Clive IA, US
Joseph Budman - Redwood City CA, US
Arthur Lo - San Francisco CA, US
Assignee:
Theravance Biopharma R&D IP, LLC - South San Francisco CA
International Classification:
A61K 31/437
A61K 45/06
A61K 9/00
A61P 31/14
Abstract:
Provided herein are methods of treating a patient infected with a coronavirus comprising administering to the patient a compound of formula 1:or a pharmaceutically-acceptable salt thereof.

Doses And Methods For Administering Telavancin

US Patent:
2018023, Aug 23, 2018
Filed:
Apr 4, 2018
Appl. No.:
15/945126
Inventors:
- South San Francisco CA, US
Arthur Lo - San Francisco CA, US
Mathai Mammen - Menlo Park CA, US
Philip Worboys - San Mateo CA, US
Assignee:
THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC - South San Francisco CA
International Classification:
A61K 38/14
A61K 9/00
A61K 47/40
Abstract:
Doses and methods for administering telavancin or a pharmaceutically-acceptable salt thereof to a human patient having an infection caused by such as bacteremia, pneumonia, endocarditis, osteomyelitis, a prosthetic joint infection or a complicated skin and skin structure infection, are disclosed. Also disclosed are methods for treating an infection caused by in a human patient using telavancin or a pharmaceutically-acceptable salt thereof. The dose of telavancin administered to the patient is determined, in part, by the weight and creatinine clearance of the patient.

Doses And Methods For Administering Telavancin

US Patent:
2016024, Aug 25, 2016
Filed:
Feb 18, 2016
Appl. No.:
15/046664
Inventors:
- South San Francisco CA, US
Arthur Lo - San Francisco CA, US
Mathai Mammen - Menlo Park CA, US
Philip Worboys - San Mateo CA, US
Assignee:
THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC - South San Francisco CA
International Classification:
A61K 38/14
A61K 47/40
A61K 9/00
Abstract:
Doses and methods for administering telavancin or a pharmaceutically-acceptable salt thereof to a human patient having an infection caused by , such as bacteremia, pneumonia, endocarditis, osteomyelitis, a prosthetic joint infection or a complicated skin and skin structure infection, are disclosed. Also disclosed are methods for treating an infection caused by in a human patient using telavancin or a pharmaceutically-acceptable salt thereof. The dose of telavancin administered to the patient is determined, in part, by the weight and creatinine clearance of the patient.

Possible Relatives

David Y Lo  Aaron C Lo  Denise A Lo  Danny S Lo  Derrick Lo  Diane Lo  Donald H Lo  Arthur J Johnson  Arthur E Stamps  Arthur A Johnston 

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.